Catalyst Wire Dossier Catalyst Wire Dossier

BESREMI

ropeginterferon alfa-2b · PharmaEssentia USA
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for BESREMI, covering 2021-11-12 to 2026-04-24. Get the full timeline:

Most recent: EMA Authorised: Besremi (ropeginterferon alfa-2b) — AOP Orphan Pharmaceuticals GmbH

See pricing